Sautebin Lidia
Department of Experimental Pharmacology, University of Naples Federico II, Naples, Italy.
Pharmacol Res. 2007 May;55(5):455-60. doi: 10.1016/j.phrs.2007.01.022. Epub 2007 Feb 17.
Despite the widespread use of cosmetic products the rate of adverse reactions (ARs) is relatively low probably because they are underestimated. This could be due to self-diagnosis and self-medication that is common in the presence of mild reactions that are frequently related to the skin. The lack of information concerning the type, number and severity of adverse reactions to cosmetics (ACRs) could be, at least in part, responsible for the absence of a reporting culture and favourable reporting environment. The aim of this study was to collect, among the countries belonging to the European Union and to the Common European Economic Space, information concerning post-marketing cosmetovigilance, particularly with respect to notification of ARs. To this aim a questionnaire was sent, by e-mail, to the competent authorities. Of the 28 countries to whom the questionnaire was sent, 10 responded by returning the filled questionnaire and 8 indicated a more appropriate address, of them only 4 replied. So, at the end of the survey, about 16 months after the first mail (June 2004), we could get information from 50% of the countries to whom the survey was addressed. The results of the research show that post-marketing vigilance system for cosmetics is different from country to country, with particular regard to notification of ARs. So in few countries there is a formal system to collect reports, in others the rules are not yet established and ACRs are collected by different authorities or there is no obligation to report ACRs or no need to collect them. Another difference concerns the procedure for reporting ACRs. In fact, among the 14 countries who have supplied information, only two collect ACRs through a reporting form. Moreover, it is interesting to note that the professional categories authorized to report, as well as state bodies who take charge of post-marketing vigilance of cosmetic products, vary from country to country. In fact, it is up to agencies for food safety, for environment or consumer protection or for public health. Besides, it must be underlined that in some countries private initiatives are undertaken, either in the presence or absence of a formal cosmetovigilance system. In conclusions, this survey shows that cosmetovigilance is differently handled in the European countries, although in some countries attempts are underway to set up a formal system. Moreover, the general impression is that an European cosmetovigilance system would be really appreciated by many countries.
尽管化妆品被广泛使用,但不良反应(ARs)的发生率相对较低,这可能是因为它们被低估了。这可能是由于自我诊断和自我用药在轻度反应中很常见,而这些反应通常与皮肤有关。关于化妆品不良反应(ACRs)的类型、数量和严重程度的信息缺乏,至少在一定程度上可能是导致缺乏报告文化和良好报告环境的原因。本研究的目的是在属于欧盟和欧洲共同经济区的国家中收集有关上市后化妆品警戒的信息,特别是关于不良反应报告的信息。为此,通过电子邮件向主管当局发送了一份调查问卷。在发送调查问卷的28个国家中,有10个国家通过返回填写好的问卷进行了回复,8个国家指出了更合适的地址,其中只有4个国家进行了回复。因此,在调查结束时,即第一次邮件发送(2004年6月)大约16个月后,我们能够从被调查国家的50%那里获得信息。研究结果表明,各国化妆品上市后警戒系统各不相同,特别是在不良反应报告方面。因此,在少数国家有正式的报告收集系统,在其他国家规则尚未建立,不良反应由不同当局收集,或者没有报告不良反应的义务或无需收集。另一个差异涉及不良反应报告程序。事实上,在提供信息的14个国家中,只有两个国家通过报告表收集不良反应。此外,有趣的是要注意到,被授权报告的专业类别以及负责化妆品上市后警戒的国家机构因国家而异。事实上,这取决于食品安全、环境或消费者保护或公共卫生机构。此外,必须强调的是,在一些国家,无论是否存在正式的化妆品警戒系统,都有私人倡议。总之,这项调查表明,欧洲国家对化妆品警戒的处理方式各不相同,尽管在一些国家正在尝试建立正式系统。此外,总体印象是,许多国家真的会欢迎一个欧洲化妆品警戒系统。